Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.47 |
| ▸ | BCHE | P06276 | 5/20 | 0.43 |
| ▸ | BACE1 | P56817 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27487738 | 0.81 | OPRK1 (0.56) | ATMOPRK1OPRD1OPRM1BACE1 | |
| SCHEMBL6318879 | 0.81 | OPRK1 (0.56) | ATMOPRK1OPRD1OPRM1BACE1 | |
| SCHEMBL5066181 | 0.81 | ALPI (0.43) | OPRK1OPRD1OPRM1ALDH1A1LMNA | |
| SCHEMBL18344466 | 0.81 | ALPI (0.43) | OPRK1OPRD1OPRM1ALDH1A1LMNA | |
| SCHEMBL4064873 | 0.81 | ALPI (0.43) | OPRK1OPRD1OPRM1ALDH1A1LMNA | |
| SCHEMBL14909569 | 0.80 | ALPI (0.46) | OPRK1OPRD1OPRM1ALDH1A1LMNA | |
| SCHEMBL14909570 | 0.80 | ALPI (0.46) | OPRK1OPRD1OPRM1ALDH1A1LMNA | |
| SCHEMBL272595 | 0.80 | ALPI (0.46) | OPRK1OPRD1OPRM1ALDH1A1LMNA | |
| SCHEMBL15656654 | 0.79 | MMP2 (0.49) | OPRK1OPRD1OPRM1ALDH1A1LMNA | |
| SCHEMBL6326395 | 0.76 | ATM (0.59) | ATMOPRK1OPRD1OPRM1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133892-B2 | Compounds that are useful for improving pharmacokinetics | ABBOTT LABORATORIES (US) | 2012-03-13 | — | — | US | disclosed |
| US-7786153-B2 | Compounds that are useful for improving pharmacokinetics | ABBOTT LABORATORIES INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20060199851-A1 | Novel compounds that are useful for improving pharmacokinetics | ABBVIE INC. | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199851-A1 | Novel compounds that are useful for improving pharmacokinetics | CYP11B1, CYP11B2, CYP7A1 | ATM 4747/4885OPRK1 576/4885OPRD1 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.